Discontinued — last reported Q2 '25
Business Segments · Exit and other-related costs
U.S. Pharmaceutical — Exit and other-related costs
Over 3 years (FY 2021 to FY 2024), U.S. Pharmaceutical — Exit and other-related costs shows a downward trend with a -35.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ3 2019
Last reportedQ2 2025
Rolls up toBusiness Exit Costs
How to read this metric
Higher costs indicate significant operational shifts or divestitures, which may signal a strategic pivot or consolidation.
Detailed definition
These are costs associated with exiting specific business activities, facilities, or product lines within the U.S. Pharm...
Peer comparison
Often categorized under restructuring or exit costs by large-scale distribution and logistics companies.
Metric ID:
mck_segment_u_s_pharmaceutical_exit_and_other_related_costsHistorical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.00M | $2.00M | $3.00M | $7.00M | $1.00M | $0.00 | $1.00M | $4.00M | $1.00M | $1.00M | $1.00M | $3.00M | $0.00 | $0.00 | $0.00 | $1.00M |
| QoQ Change | — | +0.0% | +50.0% | +133.3% | -85.7% | -100.0% | — | +300.0% | -75.0% | +0.0% | +0.0% | +200.0% | -100.0% | — | — | — |
| YoY Change | — | — | — | — | -50.0% | -100.0% | -66.7% | -42.9% | +0.0% | — | +0.0% | -25.0% | -100.0% | -100.0% | -100.0% | — |
Range$0.00 – $7.00M
CAGR-16.9%
Avg YoY Growth-58.5%
Median YoY Growth-58.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — exit and other-related costs?
- McKesson (MCK) reported u.s. pharmaceutical — exit and other-related costs of $1.00M in Q2 2025.
- What is the long-term trend for McKesson's u.s. pharmaceutical — exit and other-related costs?
- Over 3 years (2021 to 2024), McKesson's u.s. pharmaceutical — exit and other-related costs has grown at a -35.2% compound annual growth rate (CAGR), from $11.00M to $3.00M.
- What does u.s. pharmaceutical — exit and other-related costs mean?
- Expenses incurred from closing down specific operations or facilities within the U.S. Pharmaceutical segment.